Septerna, Inc. (SEPN) SEC Filings & Earnings Calls

Clinical-stage company with no approved products; pipeline risk.

“Clinical-stage biotechnology company... pipeline targets significant unmet needs.”

Clinical trial risk: SEP-479 Phase 1 data not expected until Q1 2027; potential delays or negative results.

“Phase 1 data expected Q1 2027; MAD cohorts extended to 14 days.”

Dependence on Novo Nordisk collaboration for revenue; collaboration revenue may not be sustained.

“Revenue primarily from Novo Nordisk collaboration; $26.7M in Q2 2026.”

Dependence on Novo collaboration

“Revenue is entirely from Novo; accounts receivable entirely attributed to Novo.”

Operating losses and need for future funding

“Net loss of $13.0M in Q2 2026; accumulated deficit of $188.9M.”

Early-stage development risk

“We are early in our development efforts. We have not successfully completed any advanced clinical trials.” · word for word

Substantial additional funding needed

“We will require substantial additional funding in order to finance our operations.” · word for word

Dependence on Novo collaboration

“Revenue is entirely from Novo collaboration; accounts receivable entirely attributed to Novo.”

Pre-revenue biotech (excluding collaboration revenue) with increasing R&D and G&A expenses

“R&D expenses increased 52.8% to $29.5M; G&A expenses increased 49.3% to $10.3M”

CMO departure introduces leadership transition risk

“Septerna’s Chief Medical Officer, Jae Kim, M.D., has informed the Company of his decision to pursue a new opportunity” · word for word

Early-stage clinical risk; no revenue; reliance on pipeline and collaborations.

“Forward-looking statements highlight risks in drug development, regulatory approval, and competition.”

Clinical trial failure risk

“We discontinued development of our previous lead candidate, SEP-786, following the observation of two unanticipated severe (Grade 3) events of elevated unconjugated bilirubin in the MAD portion of the Phase 1 trial.” · word for word

No approved products or revenue

“We have no products approved for commercial sale and have not generated any revenue from product sales to date” · word for word

Dependence on additional funding

“We will require substantial additional funding in order to finance our operations.” · word for word

Clinical-stage biotech with no approved products; pipeline risk.

“Clinical-stage biotechnology company... no mention of approved products.”

Clinical and regulatory risks; Phase 2b initiation subject to successful toxicology studies

“plan to initiate a Phase 2b clinical study in CSU in the second half of 2026 subject to the successful completion of long-term preclinical toxicology studies” · word for word

Forward-looking statements; no specific risk signals in excerpt

“Boilerplate safe harbor language.”

Early-stage development risk

“To date, none of the Company’s product candidates have been approved by the U.S. Food and Drug Administration (the “FDA”) for commercial sale and, therefore, the Company has not generated any revenue from product sales.” · word for word

Dependence on collaboration revenue

“For the nine months ended September 30, 2025, the Company's revenue is comprised solely of arrangements with Novo and Vertex.” · word for word

Dependence on collaboration revenue; R&D expenses increasing; clinical trial risks.

“Revenue largely from Novo Nordisk collaboration; R&D expenses up 36.5% YoY; clinical-stage pipeline.”